

On **16 July 2026** the General Pharmaceutical Council's Investigating Committee considered an allegation in relation to **Miss Aroosa MALIK, registration number: 2225303** and determined to issue the registrant concerned with a warning in relation to the conduct alleged.

The Committee concluded that the appropriate outcome in this case is a warning with the wording of:

Aroosa Malik, a registered pharmacist and Pharmacist Independent Prescriber who worked at an unregulated aesthetic clinic, Skin & Drip, London between 28 April 2025 and 12 May 2025.

- Ms Malik did not, when prescribing high-risk injectable weight loss medication Mounjaro, request face to face consultations with patients and/or contact patients directly or obtain details of their physical health in order to assess their clinical need for on-going weight loss treatment.
- Ms Malik relied principally on the information solely provided by screenshots from a non-clinical colleague within an unregulated clinic, rather than accessing the patients' records herself, in order to make her prescribing decisions.
- Ms Malik did not approach patient's GP's or obtain information providing independent confirmation of the patient's weight loss journey or medical history.
- Ms Malik did not take proper consideration of the risks associated with prescribing large quantities of weight loss medication to patients who may be vulnerable or at risk of medication abuse or dependence and ensure appropriate safety netting for these patients was in place.
- The details recorded on the prescriptions did not accurately reflect the entity issuing the prescriptions, nor provide sufficient contact details for the prescriber.

Ms Malik has breached the following GPhC standards:

- Standard 1: Provide person-centred care.
- Standard 2: Work in partnership with others.
- Standard 5: Use professional judgement.
- Standard 9: Demonstrate leadership.

Acknowledging the insight, remorse and explanation Ms Malik has provided as well as the evidence of the CPD she has completed, Ms Malik is warned that prescribing decisions made without face-to-face consultations with patients should include independent verification of information provided and should only be offered in regulated settings. Medications that are both high-risk and require on-going monitoring and management must not be prescribed unless robust systems and checks are in place to ensure patient safety from harm and ensure confidence in the profession is maintained.

This warning will be published on the register and will be available for 12 months.